Guggenheim Maintains Buy Rating on Beam Therapeutics, Lowers Price Target to $51
Guggenheim has maintained its 'Buy' rating on Beam Therapeutics while adjusting the price target from $55 to $51.
Stocks · News reference
Wedbush Adjusts Price Target on Beam Therapeutics
Wedbush maintained an Outperform rating on Beam Therapeutics while raising its price target to $30 from $28.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JonesTrading Initiates Coverage on Beam Therapeutics with Buy Rating
JonesTrading has initiated coverage on Beam Therapeutics with a 'Buy' rating and a price target of $35.
Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51
Beam Therapeutics to Present Updated BEACON Trial Data at 68th ASH Annual Meeting
Beam Therapeutics announced it will present updated clinical data from its BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel) for sickle cell disease at the upcoming American Society of Hematology (ASH) Annual Meeting.
Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30